Bitter melon (Momordica charantia)
Tropical cucurbit used across Asia and Latin America for glycaemic support, Cochrane review was inconclusive but small RCTs are modestly positive.
Why
Bitter melon (Momordica charantia, karela in India) is a widely-used food and folk medicine for diabetes across South Asia, Southeast Asia, the Caribbean and Latin America. The Cochrane review of bitter melon for type 2 diabetes (Ooi 2012) concluded that the existing trials were insufficient to determine effect, small, heterogeneous, and with methodological limitations. Smaller subsequent RCTs (Fuangchan 2011) report modest fasting-glucose reductions but smaller than metformin.
How it works
Charantin, vicine and polypeptide-p (a 17-amino-acid 'plant insulin') have hypoglycaemic effects across multiple mechanisms, increased GLUT4 translocation, reduced hepatic gluconeogenesis, and possibly direct insulin-like action.
Expected onset · Glycaemic effects over 4–8 weeks
How to take
Dosage
Standardised extract: 1,000–2,000 mg/day. Juice: 50–100 ml/day. Whole fruit consumption: regularly as part of diet.
Timing
Divided with meals
On the label
Standardised extract with stated charantin content. Whole fruit vs juice vs extract differ widely in active material.
Ideal for
Adults with prediabetes or mild type 2 diabetes exploring botanical adjuncts under clinical guidance; cultural and dietary use as a vegetable.
Safety
Evidence
Cochrane 2012 SR concluded existing evidence insufficient for clinical recommendation. Fuangchan 2011 RCT (n=143): 2 g/day bitter melon reduced HbA1c by 0.24% but was less effective than metformin 1 g/day. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.
Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation.
- Ooi et al., Cochrane Database Syst Rev 2012, Momordica charantia for type 2 diabetes mellitus
- Fuangchan et al., J Ethnopharmacol 2011, hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients (RCT)
- Yin et al., Front Endocrinol 2014, meta-analysis of Momordica charantia in type 2 diabetes
Where to get it
Shop Bitter melon (Momordica charantia) on AmazonSponsored · As an Amazon Associate, Healicus earns from qualifying purchases.